Aubrey Capital Management Ltd Makes New Investment in ADMA Biologics Inc $ADMA

Key Points

• Aubrey Capital Management Ltd has made a new investment in ADMA Biologics Inc, acquiring 189,800 shares valued at approximately $3.45 million, making it the fund's 28th largest position.
• ADMA Biologics recently reported an earnings per share of $0.15 for the last quarter, exceeding analysts' estimates by $0.01, with a revenue increase of 13.8% year-over-year.
• Analysts have given ADMA Biologics an average rating of "Buy" with a price target of $27.67, indicating positive sentiment toward the stock's future performance.

Aubrey Capital Management Ltd acquired a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 189,800 shares of the biotechnology company's stock, valued at approximately $3,455,000. ADMA Biologics accounts for about 1.2% of Aubrey Capital Management Ltd's holdings, making the stock its 28th biggest position. Aubrey Capital Management Ltd owned 0.08% of ADMA Biologics at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Skandinaviska Enskilda Banken AB publ acquired a new stake in ADMA Biologics during the 1st quarter valued at $35,000. SVB Wealth LLC acquired a new stake in ADMA Biologics during the 1st quarter valued at $35,000. Smartleaf Asset Management LLC grew its holdings in ADMA Biologics by 161.4% during the 1st quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 1,493 shares in the last quarter. Ameritas Advisory Services LLC acquired a new stake in ADMA Biologics during the 2nd quarter valued at $46,000. Finally, Toth Financial Advisory Corp grew its holdings in ADMA Biologics by 1,081.6% during the 2nd quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company's stock valued at $46,000 after purchasing an additional 2,293 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Trading Down 3.5%

NASDAQ ADMA opened at $14.56 on Friday. ADMA Biologics Inc has a 12 month low of $13.50 and a 12 month high of $25.67. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The company has a market capitalization of $3.47 billion, a price-to-earnings ratio of 16.93 and a beta of 0.47. The company's fifty day moving average price is $16.04 and its two-hundred day moving average price is $18.41.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. During the same period in the prior year, the firm posted $0.13 EPS. The firm's revenue was up 13.8% compared to the same quarter last year. As a group, research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a "buy (b-)" rating on shares of ADMA Biologics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $27.67.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.